GlassScriptPhysician profile
Sanjivan Patel
NPI 1316908171
$589.58
in general payments reported to CMS, 2019-2025
11 companies · $49.61 in 2025
The $49.61 reported for 2025 was less than what a typical Neonatal-Perinatal Medicine provider received nationally (typical 2025 total: $77.90).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2022: $26.34 · 2023: $58.43 · 2024: $105 · 2025: $49.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $124.96 | 2019 | |
| Pfizer INC. | $116.48 | 2019-2024 | |
| Gilead Sciences, INC. | $108.88 | 2019 | |
| Merck Sharp & Dohme LLC | $59.77 | 2024-2025 | |
| Glaxosmithkline, LLC. | $44.37 | 2024-2025 | Bexsero, Penmenvy |
| Guard Medical INC. | $34.68 | 2024 | Npseal Large |
| Global Blood Therapeutics, INC. | $26.34 | 2022 | |
| Brainsway USA INC | $23.65 | 2023 | |
| Emd Serono, INC. | $17.85 | 2023 | Serostim |
| Viiv Healthcare Company | $16.93 | 2023 | Rukobia |
| Phadia US INC. | $15.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjivan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.